Lewati ke konten

Informasi medis independen untuk pasien internasional

Menu

Penyakit

Lung cancer

ICD-10: C34 — Malignant neoplasm of bronchus and lung

Kelompok: Kanker Spesialisasi: Pulmonologi, Bedah Toraks

Angka utama

Hanya nilai yang diterbitkan. Setiap ubin membuka bagian yang memuat sumber, tahun, dan kalibernya.

Rincian penyakit

Nama Inggris
Malignant neoplasm of bronchus and lung

Juga dikenal sebagai

  • NSCLC
  • SCLC

Kisaran biaya pengobatan

Setiap kisaran di bawah diterbitkan pada satu dasar penagihan: Sebelum penggantian asuransi. Sumber tidak menerbitkan angka setelah penggantian, jadi tidak ada yang ditampilkan di sini.

Jalur pengobatan Kisaran biaya Dasar harga Tahun data
Pembedahan 52000 – 81790 CNY Harga paket per penyakit 2020–2025
Radioterapi 19000 – 58000 CNY Harga per item 2025–2026
Kemoterapi 6550 – 9500 CNY Harga paket per penyakit 2020–2021
Terapi bertarget 20000 – 60000 CNY Harga per item 2024–2025
Imunoterapi 32043 – 43803 CNY Harga per item 2024–2025

Batang-batang berbagi satu skala di seluruh baris di atas: masing-masing dimulai dari angka terbit terendah baris itu dan berakhir pada angka tertingginya. Angka tertinggi di halaman ini adalah 81790 CNY. Setiap baris mempertahankan tahun data dan kalibernya sendiri.

5 kisaran biaya untuk penyakit ini, dengan sumbernya di halaman baris.

Nilai yang ditulis dalam bahasa Tiongkok dikutip sebagaimana diterbitkan oleh sumber.

Lihat semua kisaran biaya →

Kelangsungan hidup lima tahun

Tingkat kelangsungan hidup 5 tahun 28.7% IK 95% 28.6–28.9

Populasi
Keseluruhan (semua stadium digabung) · Tingkat kelangsungan hidup relatif terstandar usia
Periode
2019–2021
Penerbit
Pusat Kanker Nasional Tiongkok
Sifat nilai
Nilai estimasi (analisis campuran)
Cakupan registri
281 registri kanker berbasis populasi
Ketersediaan data stadium
Tidak diterbitkan per stadium (sumber hanya menerbitkan angka keseluruhan)

Nilai yang ditulis dalam bahasa Tiongkok dikutip sebagaimana diterbitkan oleh sumber.

Lihat semua tingkat kelangsungan hidup →

Cara membaca angka ini. Angka ini diterbitkan untuk semua stadium digabung, jadi ini rata-rata atas semua orang dalam data registri nasional, bukan prognosis untuk satu orang. Pada sebagian besar kanker, stadium saat diagnosis adalah faktor tunggal terkuat di balik perbedaan kelangsungan hidup: kelangsungan hidup umumnya lebih tinggi bila kanker ditemukan pada stadium lebih dini dan lebih rendah bila ditemukan lebih lambat. Perbandingan antar kanker juga dipengaruhi oleh seberapa dini atau lambat masing-masing cenderung didiagnosis, jadi angka yang lebih rendah tidak dengan sendirinya berarti mutu layanan yang lebih buruk.

Angka itu adalah kelangsungan hidup relatif: angka ini membandingkan orang yang didiagnosis kanker ini dengan orang seusia dan sejenis kelamin dalam populasi umum, dan distandardisasi menurut umur, jadi bukan proporsi pasien yang masih hidup setelah lima tahun. Angka ini diterbitkan sebagai nilai perkiraan (analisis hibrida) karena laporan registri datang dengan jeda, sehingga National Cancer Center memodelkan periode terakhir. Sebagai konteks, sumber yang sama menerbitkan kelangsungan hidup relatif lima tahun 43,7% untuk semua kanker gabungan pada 2019–2021.

Rumah sakit dengan catatan terbit untuk penyakit ini

Dipilih menggunakan sumber data publik resmi

Rumah sakit ini dipilih dari sumber data publik resmi — peringkat reputasi spesialisasi rumah sakit Universitas Fudan, daftar spesialisasi klinis kunci nasional, dan pusat riset klinis nasional — sehingga setiap baris pada kartu dapat diperiksa terhadap sumber terbitnya. Ini bukan daftar berbayar atau promosi.

Bagaimana rumah sakit ini dipilih

Penerimaan. Sebuah rumah sakit dicantumkan untuk suatu penyakit bila spesialisasi tempat penyakit itu dikelompokkan memuat paling sedikit satu dari: posisi atau nominasi dalam peringkat reputasi spesialisasi rumah sakit Universitas Fudan; catatan spesialisasi klinis kunci nasional pada tingkat A, B, atau C; atau pusat riset klinis nasional atau laboratorium kunci negara pada spesialisasi itu. Akreditasi JCI ditampilkan sebagai lencana; akreditasi itu tidak pernah menentukan penerimaan dan tidak pernah menentukan urutan.

Urutan. Langkah 1: posisi Fudan antara 1 dan 10 untuk spesialisasi itu. Langkah 2: posisi Fudan lain, atau nominasi. Langkah 3: spesialisasi klinis kunci nasional tingkat A. Langkah 4: spesialisasi klinis kunci nasional tingkat B. Langkah 5: pusat riset klinis nasional atau laboratorium kunci negara pada spesialisasi itu, pusat sebelum laboratorium. Langkah 6: spesialisasi klinis kunci nasional tingkat C, yaitu catatan yang kami terbitkan tanpa sumber resmi independen sehingga dicantumkan setelah yang lain.

Seri. Dalam satu langkah: posisi Fudan yang lebih baik lebih dahulu, lalu tingkat spesialisasi kunci yang lebih kuat (A sebelum B sebelum C), lalu provinsi, lalu kota, lalu nama rumah sakit - urutan provinsi-kota-nama yang sama seperti yang dipakai direktori rumah sakit. Paling banyak delapan rumah sakit dicantumkan.

Bila daftar pendek. Lima rumah sakit atau lebih: delapan yang pertama dicantumkan. Tiga atau empat: semuanya dicantumkan, dan satu lipatan tambahan menambahkan catatan sisanya sampai delapan, masing-masing membawa tingkat buktinya. Satu atau dua: sama, dengan lipatan itu terbuka dan satu baris yang menyatakan berapa rumah sakit yang memiliki catatan publik kuat. Tidak ada: halaman menyatakan bahwa tidak ditemukan catatan publik kuat dan menautkan ke direktori spesialisasi. Posisi, lembaga, atau jumlah tidak pernah diciptakan untuk mengisi daftar.

Peringkat Fudan adalah peringkat reputasi spesialisasi rumah sakit yang paling luas diakui oleh dokter Tiongkok, diterbitkan setiap tahun oleh institut manajemen rumah sakit Universitas Fudan.

  1. First Affiliated Hospital of Guangzhou Medical University

    Guangzhou

    Peringkat reputasi spesialisasi Fudan 2023

    Spesialisasi klinis kunci nasional

    Platform riset

    Riset yang diterbitkan

    4 studi terbit lainnya

    PubMed mengindeks 6 makalah tentang penyakit ini yang menyebut rumah sakit ini.

    Juga diperingkat: Urologi dinominasikan dalam daftar Fudan.

  2. Cancer Hospital of Chinese Academy of Medical Sciences

    Beijing

    Peringkat reputasi spesialisasi Fudan 2023

    Spesialisasi klinis kunci nasional

    Riset yang diterbitkan

    3 studi terbit lainnya

    PubMed mengindeks 5 makalah tentang penyakit ini yang menyebut rumah sakit ini.

    Juga diperingkat: Onkologi Medis #1, Urologi dinominasikan dalam daftar Fudan.

  3. Shanghai Chest Hospital

    Shanghai

    Peringkat reputasi spesialisasi Fudan 2023

    Spesialisasi klinis kunci nasional

    Riset yang diterbitkan

    3 studi terbit lainnya

    PubMed mengindeks 5 makalah tentang penyakit ini yang menyebut rumah sakit ini.

  4. China-Japan Friendship Hospital

    Beijing

    Peringkat reputasi spesialisasi Fudan 2023

    Spesialisasi klinis kunci nasional

    Riset yang diterbitkan

    2 studi terbit lainnya

    PubMed mengindeks 4 makalah tentang penyakit ini yang menyebut rumah sakit ini.

  5. West China Hospital, Sichuan University

    Chengdu

    Peringkat reputasi spesialisasi Fudan 2023

    Spesialisasi klinis kunci nasional

    Juga diperingkat: Bedah Umum #3, Urologi #2 (seri), Otolaringologi #8 dalam daftar Fudan.

  6. Shanghai Pulmonary Hospital

    Shanghai

    Peringkat reputasi spesialisasi Fudan 2023

    Spesialisasi klinis kunci nasional

    Riset yang diterbitkan

    11 studi terbit lainnya

    PubMed mengindeks 13 makalah tentang penyakit ini yang menyebut rumah sakit ini.

  7. Peking Union Medical College Hospital

    Distrik Dongcheng

    Peringkat reputasi spesialisasi Fudan 2023

    Juga diperingkat: Bedah Umum #1, Urologi #8, Ginekologi #1 dalam daftar Fudan.

  8. Ruijin Hospital

    Shanghai

    Peringkat reputasi spesialisasi Fudan 2023

    Spesialisasi klinis kunci nasional

    Riset yang diterbitkan

    PubMed mengindeks 2 makalah tentang penyakit ini yang menyebut rumah sakit ini.

    Juga diperingkat: Bedah Umum #4, Penyakit Infeksi #6, Kedokteran Nuklir #10 dalam daftar Fudan.

Uji klinis (pengobatan dalam penelitian)

Selain perawatan standar, studi riset klinis untuk Lung cancer mungkin sedang terbuka bagi peserta di Tiongkok. Pengobatan yang diteliti belum disetujui regulator sebagai terapi standar — itu riset klinis, bukan perawatan rutin. Setiap catatan menyebutkan peneliti utama dan rumah sakit yang menjalankan studi itu. Bila Anda berminat, hubungi rumah sakit untuk menanyakan kelayakan dan tentukan sendiri apakah ingin mendaftar.

  1. Studi A Randomized, Double-Blind, Placebo-Controlled, Multi-Regional Phase III Clinical Study of Toripalimab Alone or in Combination With Tifcemalimab (JS004/TAB004) as Consolidation Therapy in Patients With Limited-Stage Small Cell Lung Cancer Without Disease Progression Following Chemoradiotherapy

    Rumah sakit
    Third Affiliated Hospital of Harbin Medical University
    Status
    Sedang merekrut
    Registri
    NCT06095583

  2. Studi A Phase 1/2 Adaptive Dose-Escalation and Expansion Study of Dual-Targeting Chimeric Antigen Receptor Natural Killer (CAR-NK) Cells Directed Against DLL3, CD56 (NCAM1), and/or GD2 in Adults With Relapsed/Refractory Small Cell Lung Cancer

    Rumah sakit
    Peking University Shenzhen Hospital
    Status
    Sedang merekrut
    Registri
    NCT07480213

  3. Studi A Multicenter, Open-label, Randomized, Prospective Clinical Study of Adebrelimab Consolidation Therapy for Limited-Stage Small-Cell Lung Cancer (LS-SCLC) Without Progression After Concurrent Chemoradiotherapy

    Peneliti utama
    Qiming Wang · Director
    Rumah sakit
    Henan Cancer Hospital
    Status
    Sedang merekrut
    Registri
    NCT07559786

  4. Studi Efficacy and Safety of Prophylactic Cranial Irradiation Versus MRI Surveillance in Patients With Limited-stage Small Cell Lung Cancer Who Achieved Remission After First-line Chemoradiotherapy: a Multicenter Randomized Controlled Phase III Clinical Trial

    Peneliti utama
    Jinming Yu · Director of Shandong Cancer Hospital and Institute
    Rumah sakit
    Shandong Cancer Hospital
    Status
    Sedang merekrut
    Registri
    NCT04829708

  5. Studi Small Extracellular Vesicle miRNAs as Predictive Biomarkers for Immunochemotherapy Efficacy in Extensive-stage Small Cell Lung Cancer

    Peneliti utama
    Wei Zhang · Chief Physician
    Rumah sakit
    Shanghai Chest Hospital
    Status
    Sedang merekrut
    Registri
    NCT07070011
136 studi terdaftar lainnya

  1. Studi A Phase II, Single-Arm, Prospective Study of Neoadjuvant Icotinib With Chemotherapy for the Treatment of Patients With Epidermal Growth Factor Receptor Mutation Positive, Resectable for Stage II to IIIB(N2) Non-small Cell Lung Cancer

    Peneliti utama
    Wu Nan · Principal Investigator
    Rumah sakit
    Peking University Cancer Hospital
    Status
    Sedang merekrut
    Registri
    NCT05104788

  2. Studi A Phase I Study to Evaluate the Safety and Preliminary Efficacy of [225Ac]Ac-DOTATATE Injection Combined With Tislelizumab in the Maintenance Treatment Period for Patients of Extensive-stage Small Cell Lung Cancer (ES-SCLC) With Somatostatin Receptors (SSTR)+ as First-line Treatment

    Rumah sakit
    Peking University Cancer Hospital
    Status
    Sedang merekrut
    Registri
    NCT07413042

  3. Studi Neoadjuvant Sintilimab or Combined With Chemotherapy for Stage III Driven Gene Mutation Negative Non-small Cell Lung Cancer

    Peneliti utama
    Peng Zhang · Director of thoracic department
    Rumah sakit
    Shanghai Pulmonary Hospital
    Status
    Sedang merekrut
    Registri
    NCT04728724

  4. Studi Disitamab Vedotin in Combination with Tislelizumab and Bevacizumab in a Phase II Clinical Study of Locally Advanced or Metastatic Non-small Cell Lung Cancer with HER2 Mutation/amplification/expression

    Peneliti utama
    Chunxia Su · Director of the Clinical Research Center
    Rumah sakit
    Shanghai Pulmonary Hospital
    Status
    Sedang merekrut
    Registri
    NCT06749860

  5. Studi Evaluation of AI-Assisted Versus Conventional Human Reading for Lung Cancer Screening in Community-Based Settings: A Randomized Controlled Trial

    Peneliti utama
    Jianxing He · Professor
    Rumah sakit
    First Affiliated Hospital of Guangzhou Medical University
    Status
    Sedang merekrut
    Registri
    NCT06988579

  6. Studi Construction and Evaluation of a Hospital-Community Health Collaboration Model Empowered by Digital Technology for Lung Cancer Screening

    Peneliti utama
    Jianxing He · Director
    Rumah sakit
    First Affiliated Hospital of Guangzhou Medical University
    Status
    Sedang merekrut
    Registri
    NCT06988943

  7. Studi Establishing a Longitudinal Cohort Study of Lung Cancer Using Tissue and Peripheral Blood Metabolomics to Explore Biomarkers and Therapeutic Mechanisms.

    Peneliti utama
    Jianxing He · Professor
    Rumah sakit
    First Affiliated Hospital of Guangzhou Medical University
    Status
    Sedang merekrut
    Registri
    NCT06843707

  8. Studi Efficiency and Safety of Microwave Ablation Plus Immune Checkpoint Inhibitor for Patients With Multiple Primary Lung Cancer: A Open, Multi-center, Phase II Clinical Trial

    Peneliti utama
    Chang Chen
    Status
    Sedang merekrut
    Registri
    NCT05053802

  9. Studi A Phase 1/2 Study Evaluating the Safety and Efficacy of Amivantamab and Olomorasib Combination Therapy in Metastatic Non-small Cell Lung Cancer

    Rumah sakit
    The First Affiliated Hospital, Sun Yat-sen University
    Status
    Sedang merekrut
    Registri
    NCT07227025

  10. Studi A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Anti-Tumor Efficacy and Safety of Sunvozertinib Versus Placebo as Adjuvant Therapy in Patients With Stage IB-IIIA Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations or PACC Mutations After Radical Surgery (WU-KONG16)

    Rumah sakit
    Peking University Cancer Hospital
    Status
    Sedang merekrut
    Registri
    NCT07182682

  11. Studi Phase II Study of Neoadjuvant CT-Guided Intra-tumor Double Checkpoint Blockades for Untreated Stage I-IIIA Non-Small Cell Lung Cancers Amenable for Surgical Resection

    Rumah sakit
    The Second Affiliated Hospital of Guangzhou Medical University
    Status
    Sedang merekrut
    Registri
    NCT06492421

  12. Studi A Phase III, Multicenter, Randomized, Controlled, Open-label Clinical Study to Evaluate the Efficacy and Safety of YL201 in Combination With Serplulimab Versus Carboplatin and Etoposide in Combination With Serplulimab as First-line Treatment in Participants With Treatment-naïve Extensive-stage Small Cell Lung Cancer

    Rumah sakit
    Sun Yat-sen University Cancer Center
    Status
    Sedang merekrut
    Registri
    NCT07739758

  13. Studi Efficacy and Safety of Cryo-Thermal Ablation Combined With Toripalimab and Chemotherapy as Neoadjuvant Treatment for Resectable Stage IB-IIIB Non-Small Cell Lung Cancer: A Multicenter, Single-Arm, Prospective Phase II Clinical Trial

    Peneliti utama
    Hu Liao · Deputy Director & Medical Team Leader, Department of Thoracic Surgery, West China Hospital, Sichuan University; Associate Professor of Surgery; Master's Supervisor
    Rumah sakit
    The Third People's Hospital of Chengdu
    Status
    Sedang merekrut
    Registri
    NCT07855965

  14. Studi A Phase 1/2 Adaptive Dose-Escalation and Expansion Study of Dual-Targeting Chimeric Antigen Receptor Natural Killer (CAR-NK) Cells Directed Against DLL3, CD56 (NCAM1), and/or GD2 in Adults With Relapsed/Refractory Small Cell Lung Cancer

    Rumah sakit
    Peking University Shenzhen Hospital
    Status
    Sedang merekrut
    Registri
    NCT07744256

  15. Studi A Phase III, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Patients With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

    Rumah sakit
    First Affiliated Hospital of Guangzhou Medical University
    Status
    Sedang merekrut
    Registri
    NCT06793215

  16. Studi A Prospective, Single Arm, Phase II Clinical Study of Tislelizumab Combined With Chemotherapy Followed by Thoracic Consolidation Radiotherapy in the First-line Treatment of Extensive Stage Small Cell Lung Cancer

    Peneliti utama
    Wei Zhou · Department Director
    Rumah sakit
    Chongqing University Cancer Hospital
    Status
    Sedang merekrut
    Registri
    NCT07425795

  17. Studi Immunonutrition in Reducing Acute Esophagitis After Thoracic Radiotherapy in Lung Cancer: a Prospective, Randomized, Controlled, Open-label Clinical Trial

    Peneliti utama
    HuaiLiu · Prof.
    Rumah sakit
    Hunan Cancer Hospital
    Status
    Sedang merekrut
    Registri
    NCT06840704

  18. Studi A Phase Ib/III Clinical Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Immunogenicity of HS-20117 Combined With Aumolertinib in Participants With Advanced Non-Squamous Non-Small Cell Lung Cancer

    Rumah sakit
    Tianjin Medical University Cancer Institute & Hospital
    Status
    Sedang merekrut
    Registri
    NCT06417008

  19. Studi A Multicenter, Open-label, Dose-Escalation and Dose-Expansion Phase I/II Study of ZG005 Combined With Gecacitinib in Patients With Advanced Non-Small Cell Lung Cancer

    Rumah sakit
    Shanghai Chest Hospital
    Status
    Sedang merekrut
    Registri
    NCT06903377

  20. Studi A Study of QL1706 Combined With Chemotherapy Induction on Sequential Immunotherapy Consolidation in Patients With Limited-Stage Small Cell Lung Cancer After Chemoradiotherapy：A Phase II Trial

    Peneliti utama
    Xuwei Cai · Director
    Rumah sakit
    Shanghai Chest Hospital
    Status
    Sedang merekrut
    Registri
    NCT07091305

  21. Studi A Multicenter, Randomized, Controlled, Open-label, Phase IIa Trial on Autologous Tumor Infiltrating Lymphocyte Injection (LM103 TILs) for the Adjuvant Treatment of Non-small Cell Lung Cancer With Negative Driver Gene Mutations

    Rumah sakit
    Guangdong Provincial People's Hospital
    Status
    Sedang merekrut
    Registri
    NCT07444437

  22. Studi Neoadjuvant Therapy With Toripalimab and JS004 Combined With Etoposide and Platinum Chemotherapy for Limited-stage Small Cell Lung Cancer : A Single-arm, Phase 2 Trial

    Peneliti utama
    Peng Zhang · Director
    Rumah sakit
    Shanghai Pulmonary Hospital
    Status
    Sedang merekrut
    Registri
    NCT06256237

  23. Studi Exploration on the Value of Molecular Residual Disease Based on Circulating Tumor DNA Detection in Predicting Recurrence of Resected Non-small Cell Lung Cancer

    Peneliti utama
    Peng Zhang · Professor
    Rumah sakit
    Shanghai Pulmonary Hospital
    Status
    Sedang merekrut
    Registri
    NCT05965024

  24. Studi Patient-derived Tumor-like Cell Cluster Model-based Precision Treatment Strategy on Non-small Cell Lung Cancer: a Prospective, Observational Study

    Peneliti utama
    Chang Chen · Deputy Director of MD. PhD. Program in Thoracic Surgery, Secretary of the party committee of Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China
    Rumah sakit
    Shanghai Pulmonary Hospital
    Status
    Sedang merekrut
    Registri
    NCT07328945

  25. Studi Safety, Tolerability, Pharmacokinetics, Immunogenicity and Preliminary Efficacy Study of the Combination Therapy With HC010 for Injection in Patients With Advanced Solid Tumors:A Multicenter, Open-Label, Dose Range-Finding and Multiple Cohort Dose Expansion Phase Ib Clinical Trial-Lung Cancer Population

    Rumah sakit
    Sun Yat-sen University Cancer Center
    Status
    Sedang merekrut
    Registri
    NCT07381829

  26. Studi A Prospective, Single-arm, Multicenter, Phase II Clinical Study on Envafolimab Combined With Disitamab Vedotin And Carboplatin for Resectable, Stage II-III, HER2-Mutant Non-Small Cell Lung Cancer

    Rumah sakit
    Guangdong Provincial People's Hospital
    Status
    Sedang merekrut
    Registri
    NCT06734182

  27. Studi A Multicenter Phase II/III Study Evaluating the Efficacy and Safety of SCTB41 Combined With Chemotherapy Versus Tislelizumab Combined With Chemotherapy as First-Line Treatment for Driver-Negative Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

    Rumah sakit
    Guangdong Provincial People's Hospital
    Status
    Sedang merekrut
    Registri
    NCT07662395

  28. Studi A Randomized, Open Label, Multicenter, Phase 3 Trial Evaluating the Efficacy and Safety of TAK-928 Versus Docetaxel in Participants With Unresectable Locally Advanced or Metastatic Non-Small Cell Lung Cancer With Disease Progression on or After Platinum-Based Chemotherapy and Anti-PD-1/PD-L1 Immunotherapy

    Rumah sakit
    The First Affiliated Hospital of Anhui Medical University
    Status
    Sedang merekrut
    Registri
    NCT07217301

  29. Studi An Open-label, Multicenter Study of ZL-1310 to Evaluate the Safety, Efficacy, and Pharmacokinetics in Participants With Small Cell Lung Cancer

    Rumah sakit
    The First Affiliated Hospital of Anhui Medical University
    Status
    Sedang merekrut
    Registri
    NCT06179069

  30. Studi Comparison of Segmentectomy Versus Lobectomy for Early-stage Non-small Cell Lung Cancer ≤ 2 cm in the Middle Third of the Lung Field: A Prospective and Multi-center RCT Study

    Rumah sakit
    Jiangsu Province Hospital
    Status
    Sedang merekrut
    Registri
    NCT04944563

  31. Studi PADL1NK-005: A Randomized, Phase 3, Open-Label Study to Evaluate PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)

    Rumah sakit
    Anhui Provincial Hospital
    Status
    Sedang merekrut
    Registri
    NCT07144280

  32. Studi DAREON ® -Lung-1: A Phase III Multi-center, Open-label, Randomised Trial of Intravenous Obrixtamig in Combination With Atezolizumab, Carboplatin, and Etoposide vs. Atezolizumab, Carboplatin, and Etoposide as First-line Treatment in Patients With Extensive-stage Small Cell Lung Cancer

    Rumah sakit
    Peking University Cancer Hospital
    Status
    Sedang merekrut
    Registri
    NCT07472517

  33. Studi A Global, Multicenter, Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan Versus Standard of Care (SOC) in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer (ES-SCLC)

    Rumah sakit
    Peking University Cancer Hospital
    Status
    Sedang merekrut
    Registri
    NCT06801834

  34. Studi A Phase 3, Multicenter, Randomized, Open-label Study Evaluating Efficacy of Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Subjects With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers, Negative for PD-L1, and Positive for KRAS p.G12C (CodeBreaK 202)

    Rumah sakit
    First Affiliated Hospital of Guangzhou Medical University
    Status
    Sedang merekrut
    Registri
    NCT05920356

  35. Studi Tranexamic Acid Use for Bleeding Prevention in the Surgical Treatment of Metastatic Spinal Tumor in Lung Cancer Patients: a Triple Blinded, Randomized Controlled Trial to Assess the Efficacy of Tranexamic Acid for Hemostasis

    Rumah sakit
    The Second Affiliated Hospital Zhejiang University School of Medicine
    Status
    Sedang merekrut
    Registri
    NCT06023212

  36. Studi A Phase I/II Multicenter, Open Label, Single-arm Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of WSD0922-FU in the Treatment of Advanced Non-small Cell Lung Cancer

    Rumah sakit
    Anhui Provincial Hospital
    Status
    Sedang merekrut
    Registri
    NCT06631989

  37. Studi Targeting Delta-like Ligand 3 (DLL3) With 68Ga-PFD3 PET/CT for the Diagnosis and Assessment of Small Cell Lung Cancer (SCLC)

    Peneliti utama
    Tingting Yuan · Attending physician
    Rumah sakit
    Peking University First Hospital
    Status
    Sedang merekrut
    Registri
    NCT07508852

  38. Studi Effectiveness of Acupuncture Combined With PD-1/PD-L1 Inhibitors for Advanced Lung Cancer：A Randomized Controlled Clinical Study

    Peneliti utama
    Liu Zhishun · professer，Chief Physician
    Rumah sakit
    The First Affiliated Hospital of Anhui Medical University
    Status
    Sedang merekrut
    Registri
    NCT06926140

  39. Studi TCR-T Cells Targeting Cancer Cells for Immunotherapy of Lung Cancer and Other Solid Tumors: Phase I Clinical Trial

    Rumah sakit
    The Second Affiliated Hospital of Guangzhou Medical University
    Status
    Sedang merekrut
    Registri
    NCT03778814

  40. Studi Observational Study on the Efficacy and Safety of Huaier Granules Compared With Platinum Containing Dual Drug Combination Chemotherapy in Adjuvant Therapy for Resectable Stage II-IIIA Non-small Cell Lung Cancer After Radical Surgery

    Peneliti utama
    Hongxu Liu · professor
    Rumah sakit
    Liaoning Cancer Hospital
    Status
    Sedang merekrut
    Registri
    NCT06109454

  41. Studi Prospective, Single-arm Phase II Clinical Study of Single-drug Chemotherapy Plus Immunotherapy in Metastatic Non-small Cell Lung Cancer Elderly Patients

    Peneliti utama
    HAN GUANG · Chief physician
    Rumah sakit
    Hubei Cancer Hospital
    Status
    Sedang merekrut
    Registri
    NCT06032052

  42. Studi ROSETTA Lung-201: A Randomized, Multicenter, Open-label Phase 3 Study of Pumitamig Monotherapy Compared to Durvalumab in Participants With Unresectable Stage III NSCLC Without Progression After Platinum-based Concurrent Chemoradiation Therapy.

    Rumah sakit
    Peking University Cancer Hospital
    Status
    Sedang merekrut
    Registri
    NCT07361497

  43. Studi A Single Arm, Open Label, Dose-escalating, Prospective Phase I Clinical Trial Evaluating the Safety, Tolerability and Efficacy of TMT101 Injection Alone in Patients With Advanced Pancreatic Cancer or Non-small Cell Lung Cancer(NSCLC) After Standard Treatment Failure

    Peneliti utama
    Wu Wenming · Director, Chief Physician of Basic Surgery, Principal Investigator, Clinical Professor
    Rumah sakit
    Peking Union Medical College Hospital
    Status
    Sedang merekrut
    Registri
    NCT06861543

  44. Studi A Prospective Cohort Study of Zorifertinib as a First-line Treatment in Patients With Epidermal Growth Factor Receptor-mutant Advanced Non-small Cell Lung Cancer With Central Nervous System (CNS) Metastases

    Rumah sakit
    The First Affiliated Hospital of Anhui Medical University
    Status
    Sedang merekrut
    Registri
    NCT07143045

  45. Studi Low-dose Radiation Therapy and Stereotactic Body Radiation Therapy Combined With PD-1 Inhibitor Sintilimab and Chemotherapy Versus PD-1 Inhibitor Combined With Chemotherapy as First-line Treatment for Patients With Locally Advanced or Metastatic Squamous Cell Lung Cancer: A Randomized, Phase II Multicenter Clinical Trial

    Peneliti utama
    You Lu · Chair of Division of Thoracic Tumor Multimodality Treatment
    Rumah sakit
    The Second Affiliated Hospital of Chongqing Medical University
    Status
    Sedang merekrut
    Registri
    NCT06121505

  46. Studi Delta-like Protein 3 (DLL3)- Targeted PET Imaging in Small Cell Lung Cancer

    Rumah sakit
    First Affiliated Hospital of Guangzhou Medical University
    Status
    Sedang merekrut
    Registri
    NCT07677787

  47. Studi Randomized, Double-Blind, Multicenter Phase III Study of RC148 in Combination With Platinum-Based Chemotherapy Versus Tislelizumab in Combination With Platinum-Based Chemotherapy as First-Line Treatment for Advanced Squamous Non-Small Cell Lung Cancer

    Rumah sakit
    The First Affiliated Hospital of Anhui Medical University
    Status
    Sedang merekrut
    Registri
    NCT07416474

  48. Studi A Phase III, Randomised, Double-blind, Placebo-controlled, Multi-centre Study of Almonertinib as Maintenance Therapy in Patients With Locally Advanced, Unresectable EGFR Mutation-positive Non-Small Cell Lung Cancer (Stage III) Who Have Not Progressed Following Definitive, Platinum-based Chemoradiation Therapy

    Rumah sakit
    Shandong Cancer Hospital
    Status
    Sedang merekrut
    Registri
    NCT04951635

  49. Studi The Therapeutic Effect of Irinotecan Liposomes Combined With Cisplatin/Carboplatin for Platinum Sensitive Recurrent Small Cell Lung Cancer

    Status
    Sedang merekrut
    Registri
    NCT06467786

  50. Studi A Phase II Clinical Study to Evaluate the Efficacy and Safety of SKB571 Combination Therapy in Participants With Non-Small Cell Lung Cancer (NSCLC)

    Rumah sakit
    Peking University Cancer Hospital
    Status
    Sedang merekrut
    Registri
    NCT07622186

  51. Studi Efficacy and Safety of PD-L1 Inhibitor Rechallenge After Immune Checkpoint Inhibitor-Related Pneumonitis in Patients With Lung Cancer: A Multicenter Real-World Study

    Rumah sakit
    First Affiliated Hospital of Guangzhou Medical University
    Status
    Sedang merekrut
    Registri
    NCT07775820

  52. Studi Tubeless Anesthesia in Preventing Contralateral Lung Complications in Patients Undergoing Single-Port Thoracoscopic Surgery for Early-Stage Lung Cancer: A Single-Center, Prospective, Open-Label, Randomized Controlled Trial

    Rumah sakit
    Fujian Medical University Union Hospital
    Status
    Sedang merekrut
    Registri
    NCT07024433

  53. Studi Effectiveness of Perioperative Percutaneous Acupoint Acupuncture on Postoperative Sleep Disturbances in Patients Undergoing Video-Assisted Thoracoscopic Lung Cancer Resection: A Prospective, Randomized, Single-Blind, Superiority Controlled Trial

    Peneliti utama
    LIna Huang · Chief Physician, Department of Anesthesiology, Shanghai First People's Hospital
    Rumah sakit
    Shanghai General Hospital
    Status
    Sedang merekrut
    Registri
    NCT07662733

  54. Studi Electroacupuncture Combined With 5-HT3 Receptor Inhibitor for the Prevention of Postoperative Nausea and Vomiting in High-risk Patients Undergoing Thoracoscopic Surgery for Lung Cancer

    Peneliti utama
    Cai Xiaoyue · Associate Chief Physician
    Rumah sakit
    Shanghai Chest Hospital
    Status
    Sedang merekrut
    Registri
    NCT07515027

  55. Studi Molecular Landscape of Primary and Acquired Resistance to Immune Checkpoint Inhibitors in Patients With Chinese Advanced Non-small Cell Lung Cancer

    Peneliti utama
    Xiaomin Niu · Principal Investigator
    Rumah sakit
    Shanghai Chest Hospital
    Status
    Sedang merekrut
    Registri
    NCT04977791

  56. Studi Randomized Controlled Study on Improving Patient-reported Outcomes After Lung Cancer Surgery With Mobile Internet Platform

    Peneliti utama
    Xinghua Cheng · Director, Head of Oncology Surgery, Clinical Professor
    Rumah sakit
    Shanghai Chest Hospital
    Status
    Sedang merekrut
    Registri
    NCT06483295

  57. Studi The Efficacy and Safety of the Combination of Sintilimab With Platinum-doublet Chemotherapy and Adaptive Radiotherapy Strategy in the Treatment of Stage III Non-small Cell Lung Cancer Patients

    Peneliti utama
    Xuewen Liu · Professor
    Rumah sakit
    Hunan Cancer Hospital
    Status
    Sedang merekrut
    Registri
    NCT07138755

  58. Studi A Phase I Clinical Study to Explore the Safety and Efficacy of Hypervision Proton Surgery (HyPROS) for Early-stage Non-small Cell Lung Cancer

    Peneliti utama
    Shuanghu Yuan · Professor
    Rumah sakit
    Anhui Provincial Hospital
    Status
    Sedang merekrut
    Registri
    NCT07195084

  59. Studi A Multicenter, Randomized, Double-blind, Phase III Clinical Study of Comparing the Efficacy and Safety of AK112 (PD-1/VEGF Bispecific Antibody) Versus Placebo as Consolidation Treatment for Patients With Limited Stage Small-Cell Lung Cancer Who Have Not Progressed Following Concurrent Chemoradiation Therapy

    Rumah sakit
    Peking University Cancer Hospital
    Status
    Sedang merekrut
    Registri
    NCT07010263

  60. Studi Prospective Cohort Study on Risk Factors and Machine Learning-Based Prediction of Postoperative Venous Thromboembolism in Patients Undergoing Lung Cancer Surgery

    Rumah sakit
    The First Hospital of Jilin University
    Status
    Sedang merekrut
    Registri
    NCT07439991

  61. Studi An Open Label, First-in-human Study of BAY 2927088 in Participants With Advanced Non-small Cell Lung Cancer (NSCLC) Harboring an EGFR and/or HER2 Mutation

    Rumah sakit
    Peking University Cancer Hospital
    Status
    Sedang merekrut
    Registri
    NCT05099172

  62. Studi Exploratory Clinical Study of Adebrelimab Combined With Chemotherapy and Concurrent Radiotherapy Versus Sequential Radiotherapy as First-Line Treatment for Extensive-Stage Small Cell Lung Cancer（ES-SCLC）.

    Peneliti utama
    Rong Yu, MD · Investigator Official Title
    Rumah sakit
    Peking University Cancer Hospital
    Status
    Sedang merekrut
    Registri
    NCT06768307

  63. Studi A Phase 3 Randomized Open-Label Study of Adjuvant Pembrolizumab With or Without MK-2870 in Participants With Resectable Stage II to IIIB (N2) NSCLC Not Achieving pCR After Receiving Neoadjuvant Pembrolizumab With Platinum-based Doublet Chemotherapy Followed by Surgery

    Rumah sakit
    Peking University Cancer Hospital
    Status
    Sedang merekrut
    Registri
    NCT06312137

  64. Studi Clinical Study of CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) for CEA Positive Advanced Lung Cancer

    Status
    Sedang merekrut
    Registri
    NCT06992583

  65. Studi Surgery or Radiotherapy After PD-L1 Inhibitor (TQB-2450) and Chemotherapy Induction Therapy in Patients With Limited-stage Small-cell Lung Cancer

    Peneliti utama
    Peng Zhang · Director of science and education department
    Rumah sakit
    Shanghai Pulmonary Hospital
    Status
    Sedang merekrut
    Registri
    NCT04539977

  66. Studi Exploring the Neo-Adjuvant Therapy Effects on Lung Cancer Through Monitoring and Assessment of Tumor Environment (NAT-LungMate)

    Peneliti utama
    Peng Zhang · Professor
    Rumah sakit
    Shanghai Pulmonary Hospital
    Status
    Sedang merekrut
    Registri
    NCT05857800

  67. Studi Multicenter, Retrospective, Observational Study of Icotinib for Post-Surgical Adjuvant Therapy in Stage IA2 High-Risk to IB Non-Small-Cell Lung Cancer With Positive EGFR-Sensitive Mutations

    Rumah sakit
    Peking University Cancer Hospital
    Status
    Sedang merekrut
    Registri
    NCT07806604

  68. Studi The Shengjing Lung Cancer Cohort (SJ-LCC) Study

    Peneliti utama
    Huanhuan Chen · Shengjing Hospital of China Medical University
    Rumah sakit
    Shengjing Hospital
    Status
    Sedang merekrut
    Registri
    NCT07779005

  69. Studi A Phase II Study Evaluating Neoadjuvant Chemotherapy, Concurrent Chemoradiotherapy Combined With Dual Immune Checkpoint Blockade (PD-1/CTLA-4) in Patients With Locally Advanced Non-Small Cell Lung Cancer

    Peneliti utama
    Hui Liu · Professor
    Rumah sakit
    Sun Yat-sen University Cancer Center
    Status
    Sedang merekrut
    Registri
    NCT07103395

  70. Studi LcProt: Proteomics Longitudinal Cohort Study on Lung CancerProspective Longitudinal Cohort Study of Lung Cancer Based on Peripheral Blood and Tissue Proteomics

    Peneliti utama
    Jianxing He · Professor
    Rumah sakit
    First Affiliated Hospital of Guangzhou Medical University
    Status
    Sedang merekrut
    Registri
    NCT06778512

  71. Studi An Apen-label, Multicenter Phase II Study to Evaluate the Efficacy and Safety of BEBT-109 in Patients With EGFR Exon 20 Insertion Mutations in Locally Advanced or Metastatic Non-Small Cell Lung Cancer

    Rumah sakit
    Guangdong Provincial People's Hospital
    Status
    Sedang merekrut
    Registri
    NCT06706713

  72. Studi Short-term Effects of Preoperative Exercise in Moderate-to-high Perioperative Risk Lung Cancer Patients(PRE-EXELUCA): a Prospective Randomized Controlled Clinical Trial

    Rumah sakit
    Guangdong Provincial People's Hospital
    Status
    Sedang merekrut
    Registri
    NCT06215326

  73. Studi Beamion 44: A Randomized, Open-label, Multi-center Phase IIa Platform Trial to Evaluate the Safety and Tolerability of Zongertinib Plus Platinum-based Doublet Chemotherapy With or Without Pembrolizumab (and Potential Other Combinations) in Treatment-naïve Patients With Locally Advanced/Metastatic Non-squamous NSCLC With Activating HER2 Mutations

    Rumah sakit
    Guangdong Provincial People's Hospital
    Status
    Sedang merekrut
    Registri
    NCT07486817

  74. Studi A Prospective, Multicenter, Randomized Controlled, Phase II Study of Probiotics Combined With Concurrent Hyperfractionated ChemoRadiotherapy and Adebrelimab Immunomaintenance in the Treatment of Limited-stage Small Cell Lung Cancer (LS-SCLC)

    Peneliti utama
    Xingwen Fan · associate professor
    Rumah sakit
    Fudan University Shanghai Cancer Center
    Status
    Sedang merekrut
    Registri
    NCT06943235

  75. Studi Mechanisms of Enhanced Efficacy of Ivonescimab in Neoadjuvant Therapy for Non-Small Cell Lung Cancer

    Peneliti utama
    Yang Fan, MD · Vice President
    Rumah sakit
    Peking University People's Hospital
    Status
    Sedang merekrut
    Registri
    NCT07359040

  76. Studi A Phase II/III Clinical Study on the Efficacy and Safety of TQB2450 Injection Combined With Chemotherapy or Anlotinib Hydrochloride Capsule in the Perioperative Treatment of Resectable Stage II/III Non Small Cell Lung Cancer.

    Rumah sakit
    Cancer Hospital of Chinese Academy of Medical Sciences
    Status
    Sedang merekrut
    Registri
    NCT05913089

  77. Studi A Phase 3, Multicenter, Randomized, Open-label Study of Ifinatamab Deruxtecan (I-DXd), a B7-H3 Antibody Drug Conjugate (ADC), Versus Treatment of Physician's Choice (TPC) in Subjects With Relapsed Small Cell Lung Cancer (SCLC) (IDeate-Lung02)

    Rumah sakit
    China-Japan Friendship Hospital
    Status
    Sedang merekrut
    Registri
    NCT06203210

  78. Studi Development and Application of a Thrombosis Risk Prediction Model in Lung Cancer Patients Treated With Immune Checkpoint Inhibitors

    Rumah sakit
    First Affiliated Hospital of Zhengzhou University
    Status
    Sedang merekrut
    Registri
    NCT06950697

  79. Studi Exploration of and Model Establishment of the Regression Pattern of Primary Lesions in Lung Cancer After Definitive Radiotherapy

    Peneliti utama
    Guangying Zhu · Clinical Professor, Chief Physician
    Rumah sakit
    China-Japan Friendship Hospital
    Status
    Sedang merekrut
    Registri
    NCT06692972

  80. Studi A Phase 1 First-in-Human Study Evaluating Safety, Pharmacokinetics and Efficacy of ABBV 324 in Adults With Hepatocellular Cancer or Squamous Cell Non-Small Cell Lung Cancer

    Rumah sakit
    Nanfang Hospital
    Status
    Sedang merekrut
    Registri
    NCT06858813

  81. Studi Cohort Studies of Associations of Psychological Stress With Therapy Efficacy and Prognosis of Lung Cancer, Including Non-small-cell Lung Cancer and Small-cell Lung Cancer With Early and Advanced Staging (STRESS-LUNG)

    Peneliti utama
    Fang Wu · Professor
    Rumah sakit
    Xiangya Hospital of Central South University
    Status
    Sedang merekrut
    Registri
    NCT05477979

  82. Studi Study of Propranolol Hydrochloride in Combination With Sintilimab and Platinum-based Chemotherapy for Treatment of Advanced Non-small Cell Lung Cancer (BRIO)

    Peneliti utama
    Fang Wu · Chief Physician, Associate Professor
    Rumah sakit
    Second Xiangya Hospital of Central South University
    Status
    Sedang merekrut
    Registri
    NCT05979818

  83. Studi The Associations of Sleep Disturbance With Therapy Efficacy and Prognosis of Lung Cancer, Including Non-small-cell Lung Cancer and Small-cell Lung Cancer With Early and Advanced Staging

    Peneliti utama
    Fang Wu · Professor
    Rumah sakit
    Xiangya Hospital of Central South University
    Status
    Sedang merekrut
    Registri
    NCT06975384

  84. Studi Comprehensive Multi-Omics Analysis of Early-Stage Lung Cancer Exhibiting Distinct Phenotypes

    Peneliti utama
    Chen Chen · Associate Professor
    Rumah sakit
    Second Xiangya Hospital of Central South University
    Status
    Sedang merekrut
    Registri
    NCT06699979

  85. Studi A Prospective, Single-Arm, Multicenter, Phase II Clinical Study of Chidamide Combined With Ivonescimab in the Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) With Acquired Resistance to Immunotherapy and High Yes-associated Protein (YAP) Expression

    Rumah sakit
    Guangdong Provincial People's Hospital
    Status
    Sedang merekrut
    Registri
    NCT07412262

  86. Studi A Phase 3, Multicenter, Randomized, Open-label Trial of Trastuzumab Deruxtecan in Combination With Pembrolizumab Versus Platinum-based Chemotherapy in Combination With Pembrolizumab, as First-line Therapy in Participants With Locally Advanced Unresectable or Metastatic HER2 Overexpressing and PD-L1 TPS <50% Non-squamous Non-small Cell Lung Cancer (DESTINY-Lung06)

    Rumah sakit
    Peking University Cancer Hospital
    Status
    Sedang merekrut
    Registri
    NCT06899126

  87. Studi Predicting Immunotherapy Response and Survival of Lung Cancer Patients Using Artificial Intelligence and Radiomics (Radiology-AI-Lung)

    Rumah sakit
    Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
    Status
    Sedang merekrut
    Registri
    NCT07059923

  88. Studi Assessment the Association of Imaging and Tumor Microenvironment in Lung Cancer With Radiogenomics

    Rumah sakit
    Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
    Status
    Sedang merekrut
    Registri
    NCT06500312

  89. Studi A Phase II Clinical Study to Evaluate the Efficacy and Safety of SI-B003 Monotherapy and BL-B01D1+SI-B003 Combination Therapy in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid Tumors

    Rumah sakit
    Chongqing University Cancer Hospital
    Status
    Sedang merekrut
    Registri
    NCT05956587

  90. Studi The Application Value of 68Ga-grazytracer PET in Immunotherapy for Stage III Non-small-cell Lung Cancer: a Prospective, Observationa Trial

    Rumah sakit
    Ruijin Hospital
    Status
    Sedang merekrut
    Registri
    NCT06623487

  91. Studi A Phase 3 Multicenter Open-label Study of Taletrectinib Versus a Standard of Care ROS1-Tyrosine Kinase Inhibitor (Crizotinib) in TKI-Naïve Patients With ROS1-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer (TRUST-III)

    Rumah sakit
    The First Affiliated Hospital of Anhui Medical University
    Status
    Sedang merekrut
    Registri
    NCT06564324

  92. Studi Impact of Intraoperative Blood Pressure Management and Dexamethasone on Patient's Outcomes After Lung Cancer Surgery: A 2 × 2 Factorial Randomized Controlled Trial

    Peneliti utama
    Dong-Xin Wang · Chairman, Department of Anaesthesiology and Critical Care Medicine
    Rumah sakit
    Peking University First Hospital
    Status
    Sedang merekrut
    Registri
    NCT04209218

  93. Studi Penpulimab-based Combination Neoadjuvant/Adjuvant Therapy for Patients With Resectable Locally Advanced Non-small Cell Lung Cancer: a Phase II Clinical Study (ALTER-L043)

    Rumah sakit
    The First Affiliated Hospital of Nanchang University
    Status
    Belum merekrut
    Registri
    NCT04846634

  94. Studi A Prospective, Multicenter Clinical Study of Hetrombopag in the Prevention of Thrombocytopenia Caused by Lung Cancer Therapy

    Peneliti utama
    Ren Shengxiang · professor
    Rumah sakit
    Jiangsu Cancer Hospital
    Status
    Belum merekrut
    Registri
    NCT07101627

  95. Studi INFORM: A Prospective Interventional Study on Early Screening for Lung Cancer Using Liquid Biopsy

    Peneliti utama
    Jianxing He · Professor
    Rumah sakit
    First Affiliated Hospital of Guangzhou Medical University
    Status
    Belum merekrut
    Registri
    NCT06422637

  96. Studi Selective Mediastinal Lymph Node Sampling Versus Systematic medIastinal Lymph Node Dissection After Neoadjuvant Chemotherapy Combined With Immunotherapy for the Treatment of Clinical Stage IIA-IIIB (N2) Non-small Cell Lung Cancer

    Peneliti utama
    Wen-zhao ZHONG · Head of Thoracic Surgery
    Rumah sakit
    Guangdong Provincial People's Hospital
    Status
    Belum merekrut
    Registri
    NCT07617389

  97. Studi Iparomlimab and Tuvonralimab (QL1706) Combined Chemotherapy and Quad Shot Radiotherapy in First-line Treatment of Driver Gene-negative Advanced Non-small Cell Lung Cancer: a Randomized, Controlled, Phase 2, Open-label Trial.

    Rumah sakit
    Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
    Status
    Belum merekrut
    Registri
    NCT07271602

  98. Studi An Open, Multi-center Phase I Clinical Trial to Evaluate the Safety, Tolerability and Preliminary Efficacy of BL0020 Injection in Combination With Toripalimab Injection in Patients With Recurrent Extensive-Stage Small Cell Lung Cancer

    Rumah sakit
    Third Affiliated Hospital of Harbin Medical University
    Status
    Belum merekrut
    Registri
    NCT07550842

  99. Studi A Single-arm, Multicenter, Prospective Clinical Study of Adebrelimab Combined With Apatinib Neoadjuvant Therapy for Resectable Non-small Cell Lung Cancer

    Rumah sakit
    First Affiliated Hospital of Xiamen University
    Status
    Belum merekrut
    Registri
    NCT07031154

  100. Studi Exploratory Clinical Study on Microwave Ablation With or Without Furmonertinib for Early-Stage Non-Small Cell Lung Cancer

    Peneliti utama
    Jiayuan Sun · Chief Physician
    Rumah sakit
    Shanghai Chest Hospital
    Status
    Belum merekrut
    Registri
    NCT06969781

  101. Studi Efficacy and Safety of Septum-guided Segmentectomy for 2-3 cm Clinical Stage IA3 Peripheral Non-Small Cell Lung Cancer: A Single-Center, Prospective, Single-Arm Clinical Trial

    Peneliti utama
    Junfeng Geng · Professor
    Rumah sakit
    Shanghai Chest Hospital
    Status
    Belum merekrut
    Registri
    NCT07780591

  102. Studi An Open-label, Single-center, Phase II Study of Cadonilimab Monotherapy as Neoadjuvant Therapy for Resectable II-IIIA Squamous Cell Lung Cancer

    Rumah sakit
    The First Hospital of Jilin University
    Status
    Belum merekrut
    Registri
    NCT05784974

  103. Studi Postoperative Adjuvant Treatment of ALK-positive Non-small Cell Lung Cancer with Ensartinib Guided by MRD: a Single-arm, Multicenter Study

    Peneliti utama
    Wu Nan · Professor
    Rumah sakit
    Peking University Cancer Hospital
    Status
    Belum merekrut
    Registri
    NCT06780839

  104. Studi Efficacy of PD-1 Inhibitor Combination Therapy in Non-small Cell Lung Cancer Patients Who Have Not Achieved Major Pathologic Response After Neoadjuvant Immunotherapy: a Multicenter, Phase II Clinical Trial

    Peneliti utama
    Chang Chen · Deputy Director of MD. PhD. Program in Thoracic Surgery, Secretary of the party committee of Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China
    Rumah sakit
    Shanghai Pulmonary Hospital
    Status
    Belum merekrut
    Registri
    NCT06620822

  105. Studi A Multicenter Randomized Controlled Trial of an Intelligent Pulmonary Function Exercise Device Versus Usual Care for In-Hospital and Home-Based Pulmonary Rehabilitation After Lung Cancer Surgery

    Peneliti utama
    Jianxing He · Principal Investigator
    Rumah sakit
    First Affiliated Hospital of Guangzhou Medical University
    Status
    Belum merekrut
    Registri
    NCT07631520

  106. Studi A Randomized Controlled Trial Evaluating the Effectiveness of a Novel Risk-Stratified Screening Strategy for Lung Cancer

    Peneliti utama
    Jianxing He · Principal Investigator
    Rumah sakit
    First Affiliated Hospital of Guangzhou Medical University
    Status
    Belum merekrut
    Registri
    NCT07078032

  107. Studi A Clinical Study Evaluating the Safety and Efficacy of Golidocitinib in Patients With Refractory Immune-related Hematologic Toxicities of Advanced Lung Cancer

    Peneliti utama
    Jianxing He · Director, Head of Thoracic Surgery, Principal Investigator, Clinical Professor
    Rumah sakit
    First Affiliated Hospital of Guangzhou Medical University
    Status
    Belum merekrut
    Registri
    NCT07303881

  108. Studi Predictive Value of CEA and ctDNA for Postoperative Recurrence in Patients With High CEA Sensitivity Lung Cancer

    Rumah sakit
    Guangdong Provincial People's Hospital
    Status
    Belum merekrut
    Registri
    NCT07170046

  109. Studi Development of a Chest CT-Based Artificial Intelligence Model Across the Lung Cancer Care Continuum and a Prospective Randomized Crossover Reader Study of Its Clinical Decision-Support Performance

    Rumah sakit
    Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
    Status
    Belum merekrut
    Registri
    NCT07829640

  110. Studi A Phase II/III Clinical Study Comparing BL-B01D1 in Combination With PD-1/VEGF Bispecific Antibody Versus Chemotherapy in Combination With PD-1/VEGF Bispecific Antibody in First-line Patients With Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer(PANKU-Lung05)

    Rumah sakit
    Sun Yat-sen University Cancer Center
    Status
    Belum merekrut
    Registri
    NCT07739199

  111. Studi The Effects of Acupuncture for Lung Cancer-Related Fatigue, a Clinical Trial

    Peneliti utama
    Yuanjie Sun · Doctor
    Rumah sakit
    Guang'anmen Hospital of China Academy of Chinese Medical Sciences
    Status
    Belum merekrut
    Registri
    NCT07079072

  112. Studi Neoadjuvant Sintilimab Plus Anlotinib Therapy in IB-IIIB Resectable Non-small Cell Lung Cancer (PRIORITY): a Prospective Single Center, Open Label, Phase II Study

    Rumah sakit
    Ningbo No.2 Hospital
    Status
    Belum merekrut
    Registri
    NCT06221462

  113. Studi A Randomized, Double-blind, Phase III Trial to Compare the Efficacy and Safety of AK104 Combined With Chemotherapy to Tislelizumab Combined With Chemotherapy as First-line Treatment in PD-L1 TPS < 1% Non-small Cell Lung Cancer (NSCLC)

    Rumah sakit
    First Affiliated Hospital of Guangzhou Medical University
    Status
    Belum merekrut
    Registri
    NCT05990127

  114. Studi Randomized Clinical Trials Comparing Immunotherapy Plus Cryoablation (I-CA) Versus Cryoablation Alone for Stage I, Selected Stage IIa, Non-Small Cell Lung Cancer

    Peneliti utama
    Jiayuan Sun · Director, Department of Respiratory Endoscopy
    Rumah sakit
    Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology
    Status
    Belum merekrut
    Registri
    NCT06580665

  115. Studi Organoid-Based Drug Sensitivity Model Guided Personalized Precision Treatment for Extensive-Stage Small Cell Lung Cancer: A Prospective, Multicenter, Randomized Controlled Trial

    Rumah sakit
    Peking Union Medical College Hospital
    Status
    Belum merekrut
    Registri
    NCT07106528

  116. Studi A Randomized Phase 3 Multicenter Open-Label Study to Compare the Efficacy of YK-029A as First-Line Treatment Versus Platinum-Based Chemotherapy in Patients With Non-Small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations

    Rumah sakit
    First Affiliated Hospital of Guangzhou Medical University
    Status
    Belum merekrut
    Registri
    NCT05767892

  117. Studi Adebrelimab and Concurrent Radiochemotherapy as First-line Treatment for Extensive-stage Small-cell Lung Cancer

    Rumah sakit
    Henan Cancer Hospital
    Status
    Belum merekrut
    Registri
    NCT06236997

  118. Studi An Investigator-initiated Trial Evaluating the Efficacy and Safety of Anti-Trop2 Universal CAR-NK(U-CAR-NK) Cells Therapy Combined With Chemotherapy for Relapsed/Refractory Non-Small Cell Lung Cancer (NSCLC)

    Peneliti utama
    Qiming Wang · Professor
    Rumah sakit
    Henan Cancer Hospital
    Status
    Belum merekrut
    Registri
    NCT06454890

  119. Studi Adebrelimab Combined With Oral Etoposide for Elderly Patients and Patients With Poor Performance Status in Small Cell Lung Cancer: An Exploratory Clinical Study

    Peneliti utama
    Liu Fang · Director
    Rumah sakit
    Third Affiliated Hospital of Harbin Medical University
    Status
    Belum merekrut
    Registri
    NCT07398560

  120. Studi Stereotactic Body Radiotherapy With Sequential Iparomlimab and Tuvonralimab (QL1706) + Chemotherapy as Neoadjuvant Therapy in Patients With Resectable Non-small-cell Lung Cancer in China (LUNG-Nanjing01): a Single-arm, Single-centre, Phase 2 Trial

    Peneliti utama
    Zhang Zhi · Associate Professor
    Rumah sakit
    Jiangsu Cancer Hospital
    Status
    Belum merekrut
    Registri
    NCT07286942

  121. Studi Efficacy and Safety of Induction Chemoimmunotherapy Followed by Carbon Ion Radiotherapy and Consolidation Immunotherapy in Unresectable Locally Advanced Non-small Cell Lung Cancer

    Peneliti utama
    Ji Yongling · PI
    Rumah sakit
    Zhejiang Cancer Hospital
    Status
    Belum merekrut
    Registri
    NCT07035860

  122. Studi A Prospective, Multicenter, Randomized Controlled Clinical Trial Comparing Bronchoscopic Thermal Vapor Ablation and Percutaneous Microwave Ablation in Patients With COPD and Early-Stage Lung Cancer: Efficacy and Safety Evaluation

    Rumah sakit
    Henan Provincial People's Hospital
    Status
    Belum merekrut
    Registri
    NCT06929390

  123. Studi Effects of Different Preoperative Oral Rehydration Protocols on Safety, Comfort, and Postoperative Outcomes in Elderly Patients Undergoing Thoracoscopic Radical Lung Cancer Surgery: A Randomized Controlled Trial

    Rumah sakit
    Fujian Medical University Union Hospital
    Status
    Belum merekrut
    Registri
    NCT07042503

  124. Studi The Impact of SGLT2i on the Outcome of Advanced Lung Cancer in Patients With Diabetes

    Peneliti utama
    Liang Zhao · Dr
    Rumah sakit
    Shanghai Chest Hospital
    Status
    Belum merekrut
    Registri
    NCT07272057

  125. Studi Phase I Study of Anti-EGFR/c-Met Bispecific Antibody MCLA-129 Combined With Befotertinib in Patients of Advanced Non-small Cell Lung Cancer With EGFR Sensitive Mutation To Evaluate The Safety, Pharmacokinetic Characteristics and Antitumor Activity

    Rumah sakit
    First Affiliated Hospital of Guangzhou Medical University
    Status
    Belum merekrut
    Registri
    NCT06015568

  126. Studi A Single-Arm Phase II Study of Intrathecal Thiotepa Via Ommaya Reservoir for Leptomeningeal Metastases in Non-Small Cell Lung Cancer Resistant to EGFR-TKI

    Rumah sakit
    Tianjin Medical University Cancer Institute & Hospital
    Status
    Belum merekrut
    Registri
    NCT07778940

  127. Studi A Prospective, Multicenter Exploratory Clinical Study on Consolidation Therapy With Tislelizumab Combined With Nintedanib for Limited-stage Small Cell Lung Cancer

    Rumah sakit
    The Affiliated Hospital of Qingdao University
    Status
    Belum merekrut
    Registri
    NCT07485920

  128. Studi A Multicenter Exploratory Clinical Study of Iruplaltinib Combined With Pemetrexed as Neoadjuvant Therapy for Resectable ALK-Positive Non-Squamous Non-Small Cell Lung Cancer

    Rumah sakit
    The First Affiliated Hospital of Fujian Medical University
    Status
    Belum merekrut
    Registri
    NCT07771764

  129. Studi Comparing the Efficiency Between Surgery and Radiotherapy After SHR-1316 (Adebrelimab) and Platinum-containing Doublet Induction Therapy for Limited-stage Small Cell Lung Cancer: a Randomized, Controlled, Open-label, Single-center Phase III Clinical Trial

    Peneliti utama
    Peng Zhang · associate professor of medicine
    Rumah sakit
    Shanghai Pulmonary Hospital
    Status
    Belum merekrut
    Registri
    NCT05496166

  130. Studi Furmonertinib Combined With Local Therapy in Inoperable or Surgery-Refusing Early-Stage Non-Small Cell Lung Cancer:A Single-arm, Phase II Study

    Peneliti utama
    Xuefei Hu · Chief Physician
    Rumah sakit
    Shanghai Pulmonary Hospital
    Status
    Belum merekrut
    Registri
    NCT07517640

  131. Studi A Phase II Clinical Study of Adebelizumab Combined With Other Anti-tumor Treatments as a Perioperative Treatment for Resectable Non-small Cell Lung Cancer

    Rumah sakit
    Shanghai Pulmonary Hospital
    Status
    Belum merekrut
    Registri
    NCT07704645

  132. Studi An Observational Study on the Impact of the 23-valent Pneumonia Vaccine on the Incidence of Pulmonary Infection and Survival in Lung Cancer Patients

    Peneliti utama
    Yalei Zhang · The First Affiliated Hospital of Guangzhou Medical University
    Rumah sakit
    First Affiliated Hospital of Guangzhou Medical University
    Status
    Belum merekrut
    Registri
    NCT07142057

  133. Studi Explore the Mechanisms Underlying Disease Resistance and Potential Primary Resistance Mechanism of Induction Therapy Lorlatinib in Resectable Non-small Cell Lung Cancer (NSCLC) Harboring ALK Positive Mutation Revealed by Single-cell RNA Sequencing and Spatial Transcriptomics

    Peneliti utama
    Jianxing He · Chief physician
    Rumah sakit
    First Affiliated Hospital of Guangzhou Medical University
    Status
    Belum merekrut
    Registri
    NCT06893354

  134. Studi Phase II, Open-label, Single-arm, Prospective, Multi-center Study to Evaluate the Efficacy and Safety of Lorlatinib as Neoadjuvant Treatment in Surgically Resectable Stage IB-IIIB ALK-rearranged Non-Small Cell Lung Cancer (NEOLORA)

    Peneliti utama
    Yang Fan, MD · Professor of Thoracic Surgery
    Rumah sakit
    Peking University People's Hospital
    Status
    Belum merekrut
    Registri
    NCT06682884

  135. Studi The Diagnostic Value of Bronchoscopic Needle-based Confocal Laser Endomicroscopy (nCLE) As a Real-time Detection Tool for Diagnosing Peripheral Lung Cancer: a Multi-centre Randomised Controlled Trial

    Peneliti utama
    Gang Hou · Professor
    Rumah sakit
    China-Japan Friendship Hospital
    Status
    Belum merekrut
    Registri
    NCT06739421

  136. Studi A Multi-cohort, Open-label Phase II Study to Evaluate the Efficacy and Safety of the Anti-EGFR/c-Met Bispecific Antibody MCLA-129 in Patients with Advanced Non-Small Cell Lung Cancer with Actionable Gene Alterations and MET Amplification.

    Rumah sakit
    The First Affiliated Hospital of Anhui Medical University
    Status
    Belum merekrut
    Registri
    NCT06885840

Halaman ini hanya membagikan informasi studi yang terdaftar secara publik. Halaman ini tidak menganjurkan atau mendorong keikutsertaan dalam studi mana pun. Keikutsertaan sepenuhnya sukarela dan risiko pengobatan yang belum disetujui tidak diketahui; hubungi rumah sakit langsung untuk kelayakan dan rincian persetujuan setelah penjelasan.

Terapi lanjutan: apa yang sudah berizin dan apa yang masih dalam uji klinis

Rumah sakit dengan catatan spesialisasi kunci nasional

Tampilkan catatan rumah sakit 46 rumah sakit dengan catatan spesialisasi kunci

Setiap baris adalah rumah sakit dengan catatan spesialisasi klinis kunci nasional pada spesialisasi tempat penyakit ini dikelompokkan. Ini catatan daftar terbit, bukan rekomendasi dan bukan peringkat.

Rumah sakit Kota Spesialisasi (sebagaimana diterbitkan) Bukti Sumber
Ruijin Hospital
Tier 3 · TERTINGGI
 Shanghai Pulmonologi Tingkat B https://www.rjh.com.cn/2018RJPortal/lcyxy2019/sy/jj/index.shtml
Shanghai General Hospital
Tier 3 · TERTINGGI
 Shanghai Pulmonologi Tingkat B https://www.firsthospital.cn/List/Depart/f0
Shanghai Pulmonary Hospital
Tier 3 · TERTINGGI
 Shanghai Pulmonologi · Bedah Toraks Tingkat B https://www.shsfkyy.com/gzb/list/b980f2cf4b134e5d85397ced965ce260/74344ed2746449a68d71c2b76c8cf423.html
Shanghai Chest Hospital
Tier 3 · TERTINGGI
 Shanghai Bedah Toraks Tingkat B https://www.shxkyy.com/hz/list/190/1400.html
Zhongshan Hospital
Tier 3 · TERTINGGI
 Shanghai Pulmonologi · Bedah Toraks Tingkat B https://www.zs-hospital.sh.cn/zhuanye/content/5140.html
Cancer Hospital of Chinese Academy of Medical Sciences Beijing Bedah Toraks Tingkat B https://www.cicams.ac.cn/news/401.html
China-Japan Friendship Hospital Beijing Pulmonologi · Bedah Toraks Tingkat B https://www.zryhyy.com.cn/zryh/c100020/202309/47e8245aa93343baac89762d4e80580f.shtml
Beijing Hospital
Tier 3 · TERTINGGI
 Beijing Pulmonologi · Bedah Toraks Tingkat B https://www.bjhmoh.cn/index.php?id=4&r=archives/about&t=1790009033
Peking University People's Hospital Beijing Pulmonologi · Bedah Toraks Tingkat B https://www.pkuph.cn/news_details/26715.html
Peking University First Hospital Beijing Bedah Toraks Tingkat B https://www.pkufh.com/Html/News/Articles/64494.html
Peking University Third Hospital Beijing Pulmonologi Tingkat B https://www.puh3.net.cn/yygk/zdxk.htm
Beijing Chao-Yang Hospital, Capital Medical University Beijing Pulmonologi Tingkat B https://www.bjcyh.com.cn/Html/News/Articles/21528.html
West China Hospital, Sichuan University
Tier 3 · TERTINGGI
 Chengdu Pulmonologi · Bedah Toraks Tingkat A https://wcums.scu.edu.cn/kxyan_jiu/gjlczdzk.htm
Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital
Tier 3 · TERTINGGI
 Chengdu Pulmonologi Tingkat B https://www.samsph.com/introduce/
Tianjin Medical University General Hospital
Tier 3 · TERTINGGI
 Tianjin Pulmonologi Tingkat B https://www.tjmugh.com.cn/system/2019/01/02/020008655.shtml
Tianjin Medical University Cancer Institute & Hospital Tianjin Bedah Toraks Tingkat B https://www.tjmuch.com/yygk/yyjj/index_yg.shtml
The First Affiliated Hospital of Anhui Medical University Hefei Pulmonologi Tingkat B https://www.ayfy.com/info/1184/27750.htm
Qilu Hospital of Shandong University
Tier 3 · TERTINGGI
 Jinan Pulmonologi · Bedah Toraks Tingkat A http://wsjkw.shandong.gov.cn/wmfw/cxfw/202307/P020230717441794577839.xlsx
Shandong Provincial Qianfoshan Hospital Jinan Pulmonologi · Bedah Toraks Tingkat A http://wsjkw.shandong.gov.cn/wmfw/cxfw/202307/P020230717441794577839.xlsx
https://file.byfy.cn/Resource/File/Upload/file/20251204/20251204085449_9136.pdf
Sun Yat-sen University Cancer Center Guangzhou Bedah Toraks Tingkat B https://sysucc.org.cn/department/introduction/41
The First Affiliated Hospital, Sun Yat-sen University Guangzhou Pulmonologi · Bedah Toraks Tingkat B https://gcp.fahsysu.org.cn/sites/1h.gcp.sysucloud1.sysu.edu.cn/files/2023-07/20230625%20中山大学附属第一医院宣传折页%20V5.0_0.pdf
Nanfang Hospital Guangzhou Pulmonologi Tingkat A https://portal.smu.edu.cn/yzw/info/1023/11291.htm
Guangdong Provincial People's Hospital Guangzhou Bedah Toraks Tingkat B https://static.nfnews.com/content/202503/22/c11108498.html
First Affiliated Hospital of Guangzhou Medical University
Tier 3 · TERTINGGI
 Guangzhou Pulmonologi · Bedah Toraks Tingkat B https://www.gyfyyy.cn/cn/news/xwsd/index_88.html
Jiangsu Province Hospital
Tier 3 · TERTINGGI
 Nanjing Pulmonologi Tingkat B https://www.jsph.org.cn/ksjj/ksjs/nk1/hxywzzyxk.htm
Jiangsu Cancer Hospital
Tier 3 · TERTINGGI
 Nanjing Bedah Toraks Tingkat B https://www.jszlyy.com.cn/home/news/content/id/476/pid/47579
Henan Provincial People's Hospital Zhengzhou Pulmonologi Tingkat B https://www.hnsrmyy.net/jzzn/ksdh/nk/hxywzzyxk/ksjj.htm
Henan Cancer Hospital Zhengzhou Bedah Toraks Tingkat B https://www.anti-cancer.com.cn/Html/News/Articles/13202.html
First Affiliated Hospital of Zhengzhou University Zhengzhou Pulmonologi · Bedah Toraks Tingkat B Tingkat C https://www.zdyfy.cn/tsyl/gjjlczdzk
Tidak diterbitkan
The First Affiliated Hospital, Zhejiang University School of Medicine
Tier 3 · TERTINGGI
 Hangzhou Pulmonologi Tingkat A http://zdygb.zju.edu.cn/2014/0106/c34026a1762975/page.htm
The Second Affiliated Hospital Zhejiang University School of Medicine
Tier 3 · TERTINGGI
 Hangzhou Pulmonologi Tingkat A http://zdygb.zju.edu.cn/2014/0106/c34026a1762975/page.htm
Sir Run Run Shaw Hospital Affiliated with Zhejiang University School of Medicine
Tier 3 · TERTINGGI
 Hangzhou Pulmonologi Tingkat B https://www.srrsh.com/sywhInfo/536
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology Wuhan Pulmonologi · Bedah Toraks Tingkat B https://www.whuh.com/kxyj/xkjs/gjlczdzk.htm
https://www.whuh.com/kxyj/xkjs/gjlczdzk/2.htm
Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology
Tier 3 · TERTINGGI
 Wuhan Pulmonologi · Bedah Toraks Tingkat B https://www.tjh.com.cn/contents/934/27291.html
Renmin Hospital of Wuhan University Wuhan Bedah Toraks Tingkat B https://www.rmhospital.com/article/id/16939.html
Third Xiangya Hospital
Tier 3 · TERTINGGI
 Changsha Pulmonologi Tingkat B https://www.xy3yy.com/ksjj/184173.html
Second Xiangya Hospital of Central South University Changsha Pulmonologi · Bedah Toraks Tingkat B https://www.xyeyy.com/655/656/664/
Xiangya Hospital of Central South University
Tier 3 · TERTINGGI
 Changsha Pulmonologi Tingkat B https://www.xiangya.com.cn/zdzk.html
Shengjing Hospital
Tier 3 · TERTINGGI
 Shenyang Pulmonologi · Bedah Toraks Tingkat B https://www.sj-hospital.cn/article/2816.html
https://www.sj-hospital.org/sjweekly/resfile/2024-01-26/16/sjzk-20240126-016.pdf
First Hospital of China Medical University
Tier 3 · TERTINGGI
 Shenyang Pulmonologi · Bedah Toraks Tingkat A Tingkat B https://www.cmu1h.com/features/specialty
https://wsjk.ln.gov.cn/wsjk/index/gsgg/D6FB5218203A456D9540155A2D928D84/index.shtml
Liaoning Cancer Hospital
Tier 3 · TERTINGGI
 Shenyang Bedah Toraks Tingkat B https://www.lnchi.org.cn/ch/hospital/biref/index.html
The First Affiliated Hospital of Chongqing Medical University Chongqing Pulmonologi · Bedah Toraks Tingkat B https://www.hospital-cqmu.com/gzb/yygk/yyjj.htm
The Second Affiliated Hospital of Chongqing Medical University Chongqing Pulmonologi Tingkat B https://www.cqsahcqmu.cn/mobile/index.php?c=category&id=1013
The First Affiliated Hospital of Xi'an Jiaotong University
Tier 3 · TERTINGGI
 Xi'an Pulmonologi · Bedah Toraks Tingkat B https://news.xjtu.edu.cn/info/1033/17951.htm
http://www.dyyy.xjtu.edu.cn/info/41461/122341.htm
The Second Affiliated Hospital of Xi'an Jiaotong University
Tier 3 · TERTINGGI
 Xi'an Pulmonologi Tingkat B https://news.xjtu.edu.cn/info/1219/169067.htm
Shaanxi Provincial People's Hospital Xi'an Pulmonologi Tingkat B https://www.spph-sx.com/zlfw1/zdzk.htm

46 rumah sakit dengan catatan spesialisasi kunci nasional yang cocok.

Nilai yang ditulis dalam bahasa Tiongkok dikutip sebagaimana diterbitkan oleh sumber.

Apa yang dilaporkan pasien

Hanya angka agregat: hasil nasional yang dikutip dengan sumbernya dan tahun yang dirujuknya. Ini bukan testimoni pasien dan bukan pernyataan tentang satu orang.

  • Sebagaimana dilaporkan dalam National Health Commission - 2023 national tertiary public hospital performance monitoring circular (国卫医政函〔2025〕55 号) (2023): National inpatient satisfaction / outpatient satisfaction — 95.42 / 93.95 score, 0-100.

    National aggregate across the 2,168 tertiary public hospitals that took part in the national performance monitoring (all conditions combined; not disease-specific, not hospital-specific).

    Sumber: National Health Commission - 2023 national tertiary public hospital performance monitoring circular (国卫医政函〔2025〕55 号) — https://www.gov.cn/zhengce/zhengceku/202503/content_7016208.htm — 2023 — Tingkat A

Efek samping yang dilaporkan

Tingkat satu efek samping dalam satu uji klinis, dikutip dengan sumbernya dan tanggal pengambilannya. Ini tingkat satu uji, bukan tingkat nasional.

  • Sebagaimana dilaporkan dalam ClinicalTrials.gov results - NCT01310036 (2026-10-05): Pneumonia (serious adverse event) — 10 / 207 (about 4.8%) participants.

    Single trial: erlotinib 150 mg daily, safety population n=207, systematic assessment, MedDRA 19.1, 5% frequency threshold. It is a single-trial rate for one study population, not a national rate.

    Sumber: ClinicalTrials.gov results - NCT01310036 — https://clinicaltrials.gov/api/v2/studies/NCT01310036 — 2026-10-05 — Tingkat B

Semua topik terapi & akses

Pertanyaan tentang penyakit ini

Kami tidak dapat memberikan nasihat medis, tetapi kami dapat menjawab pertanyaan tentang halaman ini dan tentang mengatur pengobatan di Tiongkok.

Tanyakan kepada kami tentang kondisi ini

Kode ICD

Tampilkan tabel kode 7 kode ICD
Versi Kode Nama dalam versi itu
ICD-10-WHO C34 Malignant neoplasm of bronchus and lung
ICD-10-WHO C34.0 Main bronchus
ICD-10-WHO C34.1 Upper lobe, bronchus or lung
ICD-10-WHO C34.2 Middle lobe, bronchus or lung
ICD-10-WHO C34.3 Lower lobe, bronchus or lung
ICD-10-WHO C34.8 Overlapping lesion of bronchus and lung
ICD-10-WHO C34.9 Bronchus or lung, unspecified

Baris-barisnya adalah entri ICD-10 WHO untuk penyakit ini, dikutip sebagaimana diterbitkan.

Sumber & bukti

URL sumber
https://wjw.fujian.gov.cn/xxgk/fgwj/zxwj/201904/P020190412506737868905.xlsx
Skema sumber
https
Jenis sumber
Komisi kesehatan provinsi
Tingkat bukti
A - dinyatakan oleh komisi kesehatan, lembaga riset nasional, atau universitas
Diambil pada
2026-09-24